Category Pharma/Biotech

Biocytogen Refutes Harbour BioMed's Patent Claims, Asserts RenNano® Is Independently Developed and Legally Robust

Biocytogen Refutes Harbour BioMed’s Patent Claims, Asserts RenNano® Is Independently Developed and Legally Robust

In response to Harbour BioMed’s recent press release regarding a decision in its pending lawsuit, Biocytogen is issuing the following statement: Biocytogen operates in accordance with its core values: independent innovation,…

Read MoreBiocytogen Refutes Harbour BioMed’s Patent Claims, Asserts RenNano® Is Independently Developed and Legally Robust
Valar Labs’ CHAI Biomarkers Validated in New Study in European Urology for Predicting Outcomes of High Grade Ta Bladder Cancer

Valar Labs’ CHAI Biomarkers Validated in New Study in European Urology for Predicting Outcomes of High Grade Ta Bladder Cancer

Valar Labs, a pioneer in AI-powered diagnostics for oncology, announced the publication of its latest research in European Urology, the highest-impact journal in the field of urology. The peer-reviewed study highlights…

Read MoreValar Labs’ CHAI Biomarkers Validated in New Study in European Urology for Predicting Outcomes of High Grade Ta Bladder Cancer
Cybin Shares Corporate Update and Positive Regulatory Progress for Psychedelic Therapies

Cybin Shares Corporate Update and Positive Regulatory Progress for Psychedelic Therapies

Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today provided…

Read MoreCybin Shares Corporate Update and Positive Regulatory Progress for Psychedelic Therapies
Astria Therapeutics Shares Promising Early Data from Navenibart Trial in Hereditary Angioedema at EAACI Congress

Astria Therapeutics Shares Promising Early Data from Navenibart Trial in Hereditary Angioedema at EAACI Congress

 a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive initial results from the target enrollment group in the ongoing ALPHA-SOLAR long-term open-label trial…

Read MoreAstria Therapeutics Shares Promising Early Data from Navenibart Trial in Hereditary Angioedema at EAACI Congress